ECSP14006696A - Agentes de reversión anticoagulante - Google Patents

Agentes de reversión anticoagulante

Info

Publication number
ECSP14006696A
ECSP14006696A ECIEPI20146696A ECPI201406696A ECSP14006696A EC SP14006696 A ECSP14006696 A EC SP14006696A EC IEPI20146696 A ECIEPI20146696 A EC IEPI20146696A EC PI201406696 A ECPI201406696 A EC PI201406696A EC SP14006696 A ECSP14006696 A EC SP14006696A
Authority
EC
Ecuador
Prior art keywords
compounds
reversal agents
anticoagulant
anticoagulant reversal
methods
Prior art date
Application number
ECIEPI20146696A
Other languages
English (en)
Inventor
Sasha Bakhru
Bryan Laulicht
Edith Mathiowitz
Solomon Steiner
Original Assignee
Perosphere Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47430065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14006696(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Perosphere Inc filed Critical Perosphere Inc
Publication of ECSP14006696A publication Critical patent/ECSP14006696A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen compuestos de reversión de anticoagulantes novedosos, así como también métodos para fabricar los compuestos, composiciones farmacéuticas que incluyen los compuestos, métodos para utilizar los compuestos para revertir los efectos anticoagulantes de los inhibidores de la coagulación y ensayos de diagnóstico que comprende los compuestos.
ECIEPI20146696A 2011-11-29 2014-06-26 Agentes de reversión anticoagulante ECSP14006696A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161564559P 2011-11-29 2011-11-29
US201261614292P 2012-03-22 2012-03-22
US201261641698P 2012-05-02 2012-05-02
US201261666291P 2012-06-29 2012-06-29

Publications (1)

Publication Number Publication Date
ECSP14006696A true ECSP14006696A (es) 2015-06-30

Family

ID=47430065

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI20146696A ECSP14006696A (es) 2011-11-29 2014-06-26 Agentes de reversión anticoagulante

Country Status (34)

Country Link
US (5) US9522892B2 (es)
EP (1) EP2785700B1 (es)
JP (1) JP6134731B2 (es)
KR (1) KR101892330B1 (es)
CN (1) CN104080772B (es)
AP (1) AP2014007662A0 (es)
AR (1) AR089020A1 (es)
AU (1) AU2012345975B2 (es)
BR (1) BR112014012892B1 (es)
CA (1) CA2856540C (es)
CL (1) CL2014001399A1 (es)
CO (1) CO6990738A2 (es)
CR (1) CR20140310A (es)
CY (1) CY1117414T1 (es)
DK (1) DK2785700T3 (es)
EA (1) EA027603B1 (es)
EC (1) ECSP14006696A (es)
ES (1) ES2569674T3 (es)
HR (1) HRP20160513T1 (es)
HU (1) HUE027452T2 (es)
IL (1) IL232788B (es)
ME (1) ME02424B (es)
MX (1) MX349514B (es)
PE (1) PE20141295A1 (es)
PH (1) PH12014501176B1 (es)
PL (1) PL2785700T3 (es)
PT (1) PT2785700E (es)
RS (1) RS54738B1 (es)
SG (1) SG11201402713WA (es)
SI (1) SI2785700T1 (es)
SM (1) SMT201600161B (es)
UA (1) UA116336C2 (es)
WO (1) WO2013082210A1 (es)
ZA (1) ZA201404793B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9999690B2 (en) 2013-11-08 2018-06-19 Perosphere Pharmaceuticals Inc. Labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds
CN114456176B (zh) 2016-03-28 2024-08-30 因赛特公司 作为tam抑制剂的吡咯并三嗪化合物
KR102739325B1 (ko) 2017-09-27 2024-12-09 인사이트 코포레이션 Tam 억제제로서 유용한 피롤로트리아진 유도체의 염
AU2018365257B2 (en) * 2017-11-13 2021-05-13 Maximum Fidelity Surgical Simulations, Inc. Reconstitution of post mortem circulation, specialized methods and procedures
US11241438B2 (en) 2018-06-29 2022-02-08 Incyte Corporation Formulations of an AXL/MER inhibitor
US11716989B2 (en) 2019-04-16 2023-08-08 Maximum Fidelity Surgical Simulations, LLC Cadaver preservation systems and methods
US11915610B2 (en) 2019-05-15 2024-02-27 Maximum Fidelity Surgical Simulations, LLC Cadaverous heart model
CN112010930B (zh) * 2019-05-28 2022-08-02 首都医科大学 Rgd修饰的五环哌嗪二酮及其制备和应用
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
JP2026511191A (ja) 2023-03-24 2026-04-10 シャンシー・ミコ・ファーマシューティカル・テクノロジー・カンパニー，リミテッド 抗凝固逆転剤及びその製造方法、並びにその応用
CN117624137A (zh) * 2023-12-04 2024-03-01 中国药科大学 三嗪骨架小分子肝素逆转剂及其制备方法与用途
US20250389737A1 (en) * 2024-06-20 2025-12-25 Instrumentation Laboratory Company FACTOR Xa REAGENT
EP4667582A1 (en) * 2024-06-20 2025-12-24 Instrumentation Laboratory Company Factor xa reagent
CN121622691A (zh) * 2024-08-30 2026-03-10 陕西麦科奥特医药科技股份有限公司 使用抗凝逆转剂治疗抗凝剂导致的出血的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3678157A (en) * 1968-10-23 1972-07-18 Oreal Hair treatment compositions containing polycondensable compounds
IL115420A0 (en) * 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
US6069232A (en) * 1995-10-02 2000-05-30 Hoechst Marion Roussel, Inc. Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors
US6080852A (en) 1996-06-27 2000-06-27 The Perkin-Elmer Corporation 4,7-dichlororhodamine dyes
CA2268381A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
PL336233A1 (en) * 1997-04-07 2000-06-19 Axys Pharm Inc Compounds and agents for treating diseases associated with serinic protease activity, in particular tryptase activity
FR2781221B1 (fr) * 1998-07-17 2000-10-13 Lafon Labor Piperazinones substituees en alpha
CA2348740A1 (en) * 1998-12-23 2000-07-06 Ruth R. Wexler Thrombin or factor xa inhibitors
CA2373610A1 (en) 1999-05-19 2000-11-23 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
EP1377554A1 (en) 1999-06-16 2004-01-07 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
JP2004501077A (ja) 2000-04-17 2004-01-15 ファルマシア・コーポレーション 凝固カスケードの選択的阻害に有用な多環式アリールおよびヘテロアリール置換１，４−キノン
AU2001275857A1 (en) * 2000-06-29 2002-01-14 Bristol-Myers Squibb Pharma Company Thrombin or factor xa inhibitors
BR0213092A (pt) 2001-10-03 2004-10-19 Pharmacia Corp Compostos heterocìclicos de 6 elementos úteis para a inibição seletiva da cascata de coagulação
AU2003217028A1 (en) 2002-03-27 2003-10-13 Cambridge University Technical Services Ltd Diaminoacid-aminoacid-polyamine based gemini surfactant compounds
US20060233786A1 (en) * 2002-05-23 2006-10-19 Chugai Seiyaku Kabushiki Kaisha Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation
GB0214122D0 (en) 2002-06-19 2002-07-31 Eastman Kodak Co High contrast photographic element containing a polyhydrazide nucleating agent
SE0400014D0 (sv) * 2004-01-08 2004-01-08 Astrazeneca Ab Heterocyclic derivatives
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
WO2008105441A1 (ja) * 2007-02-27 2008-09-04 Ajinomoto Co., Inc. リン吸収抑制活性を有するポリアミノ酸化合物及びリン吸収抑制剤
EP2193196B1 (en) * 2007-09-28 2016-07-13 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
GB2476643B (en) 2009-12-23 2012-11-14 Haomamedica Ltd 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants
TWI513466B (zh) 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
PE20140964A1 (es) 2011-03-30 2014-08-17 Boehringer Ingelheim Int Antidotos anticoagulantes

Also Published As

Publication number Publication date
IL232788A0 (en) 2014-08-03
MX2014006349A (es) 2014-09-04
AP2014007662A0 (en) 2014-05-31
KR20140107259A (ko) 2014-09-04
AU2012345975B2 (en) 2016-12-15
US9877961B2 (en) 2018-01-30
PH12014501176A1 (en) 2014-09-01
BR112014012892A2 (pt) 2017-06-13
US9522892B2 (en) 2016-12-20
UA116336C2 (uk) 2018-03-12
ES2569674T3 (es) 2016-05-12
EP2785700A1 (en) 2014-10-08
CA2856540A1 (en) 2013-06-06
ME02424B (me) 2016-09-20
RS54738B1 (sr) 2016-10-31
PT2785700E (pt) 2016-06-02
PL2785700T3 (pl) 2016-09-30
CA2856540C (en) 2018-04-03
EA201490823A1 (ru) 2015-01-30
HUE027452T2 (en) 2016-09-28
CN104080772B (zh) 2016-10-05
SG11201402713WA (en) 2014-06-27
JP6134731B2 (ja) 2017-05-24
ZA201404793B (en) 2015-04-29
US20130137702A1 (en) 2013-05-30
MX349514B (es) 2017-08-02
SMT201600161B (it) 2016-07-01
US20180207152A1 (en) 2018-07-26
EA027603B1 (ru) 2017-08-31
AR089020A1 (es) 2014-07-23
WO2013082210A1 (en) 2013-06-06
SI2785700T1 (sl) 2016-09-30
CR20140310A (es) 2014-08-20
IL232788B (en) 2018-05-31
BR112014012892B1 (pt) 2022-12-20
EP2785700B1 (en) 2016-03-09
BR112014012892A8 (pt) 2021-06-08
JP2014534270A (ja) 2014-12-18
CL2014001399A1 (es) 2014-11-03
US20210169874A1 (en) 2021-06-10
HRP20160513T1 (hr) 2016-07-15
US20170056396A1 (en) 2017-03-02
DK2785700T3 (en) 2016-06-13
HK1202858A1 (en) 2015-10-09
KR101892330B1 (ko) 2018-08-27
CN104080772A (zh) 2014-10-01
PE20141295A1 (es) 2014-10-01
CO6990738A2 (es) 2014-07-10
NZ625337A (en) 2016-11-25
PH12014501176B1 (en) 2014-09-01
CY1117414T1 (el) 2017-04-26
US20240366592A1 (en) 2024-11-07
AU2012345975A1 (en) 2014-05-29

Similar Documents

Publication Publication Date Title
CO6990738A2 (es) Agentes de reversion anticoagulante
CR20140275A (es) Triazolopiridinas sustituidas
JOP20180103A1 (ar) مركب صيدلاني
CR20130616A (es) Amidas-2-piridina útiles como agonistas cb2
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
ECSP14004976A (es) Anticuerpos anti-il-36r
EA201491303A1 (ru) Конденсированные тетра- или пентациклические дигидродиазепинокарбазолоны в качестве ингибиторов parps
GT201400136A (es) Compuestos y métodos de benzaldehído substituído para su uso en incrementar la oxigenación de los tejidos
CL2014001291A1 (es) Agentes de iarn de doble hebra; composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr).
MX338078B (es) Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos.
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
ECSP14013251A (es) Derivados de 5-flúor-4-imino-3-(sustituido)-3,4-dihidropirimidin-2(1h)ona
NI201400079A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20150250A (es) Nuevos derivados de piridina
EA201491304A1 (ru) Конденсированные тетра- или пентациклические пиридофталазиноны в качестве ингибиторов parp
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
CR20150204A (es) Nuevos derivados de piridina
DOP2013000307A (es) Antagonistas de trpv4
UY34097A (es) Alineación de anticoagulante de cebado para extracción de sangre.
CR20130539A (es) Triazolopiridinas
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2